药价监管的法治问题研究  

Research on the legal issues of drug price supervision

作　　者：牟霞 羊海燕 Mou Xia;Yang Haiyan(Southwest Medical University School of Law,Luzhou,Sichuan 646600,China)

机构地区：[1]西南医科大学法学院,四川泸州市646600

出　　处：《卫生法学》2024年第4期19-23,79,共6页Health Law

基　　金：四川省哲学社会科学重点研究基地--四川医事卫生法治研究中心立项资助的项目“健康中国背景下突发公共卫生应急药品保障的法律进路研究”(YF23-Q06);泸州市哲学社会科学研究规划课题项目“公共治理能力视阈下应急药品供应保障研究--以泸州市为例”(LZ23A037)的阶段性成果

摘　　要：3年疫情之后,民众已然成为健康的第一责任人,保障药品的可及性与可负担性是提升民众健康的刚性需求。以降低药价、保障人民群众药品可及性以及可负担性的药价改革措施频繁进行,但是改革实效却始终与药价改革预期目标存在差距,与之配套的《药品管理法》并未从根源上解决药价监管问题。根本原因是现存法律制度忽视了药品价格监管困境的根源在于信息不对称。以准公共产品理论剖析药品的特殊性,为药品价格有别于普通商品的监管提供正当性和合法性,以“委托-代理”分析药品市场信息不对称现状,从根本上解决药价监管的难点与痛点,为扎实推进“健康中国”的“最后一公里”提供支撑。After three years of epidemics,people have become the first responsible for their health,and the guarantee of accessibility and affordability of medicines is a rigid demand to improve people's health.The drug price reform measures to reduce drug prices and ensure the accessibility and affordability of drugs for the public have been carried out frequently,but the effectiveness of the reform has always been different from the expected goal of the drug price reform,and the Drug Administration Law has not solved the problem of drug price regulation from the root.The fundamental reason is that the existing legal system involves the neglect of the drug price regulation dilemma rooted in information asymmetry.This paper analyzed the special characteristics of drugs with the quasi-public product the-ory,provided legitimacy and legality for the regulation of drug prices different from ordinary commodities,analyzed the sta-tus quo of information asymmetry in the drug market with the"principal-agent",solved the difficulties and pain points in the regulation of drug prices at the root,and promoted the"last step"of Healthy China.

关 键 词：委托-代理 信息不对称 准公共产品 药价监管 

分 类 号：D902[政治法律—法学理论]